A recent article published in the journal Chest details the management of idiopathic pulmonary fibrosis in elderly patients from seven aspects, including diagnosis, comorbidities and complications, treatment, and prognosis, which is compiled below: Idiopathic pulmonary fibrosis is closely associated with advanced age. Confirmation of the diagnosis of idiopathic pulmonary fibrosis is critical, as the diagnosis of the disease can enable only one of the many potential causes remaining in elderly patients with recognized interstitial lung disease. Optimal management of idiopathic pulmonary fibrosis, especially in the elderly, depends on several factors: balancing the provision of standard measures of health care with the overall health status of the patient (robustness or vulnerability), and considering the patient’s hopes, desires and expectations. Idiopathic pulmonary fibrosis is known to be associated with a number of common complications in the elderly. Nowadays, pharmacological treatment of idiopathic pulmonary fibrosis is limited and included in the treatment, such as the use of immunosuppressive drugs to treat idiopathic pulmonary fibrosis, which undoubtedly poses a significant risk to the elderly. Nevertheless, anti-fibrotic drugs such as pirfenidone and nidanib for the treatment of idiopathic pulmonary fibrosis have been developed on a commercial scale in the United States. In older adults with co-morbidities, monitoring and treatment of idiopathic pulmonary fibrosis requires consideration of adverse side effects, avoidance of drug-drug interactions, treatment of comorbidities, and timely implementation of mitigation measures. The development of individualized counseling to guide decision-making and improve quality of life can simultaneously optimize the overall management of idiopathic pulmonary fibrosis in the elderly. In developed countries or in the medical literature, older adults are defined as those aged 65 years and older. Because of the aging process, older individuals manifest a degradation of organ system function, meaning that molecular, cellular, and tissue damage is accumulating throughout life. However, there are individual differences in the rate of aging. Some individuals over the age of 60 maintain robust physiological function, while others experience progressive decline in their own organ systems as they progress in age. Various types of interstitial lung disease can occur at any age, but in the case of idiopathic pulmonary fibrosis, it is strongly associated with advanced age and has a high prevalence in the elderly population. Clinical evaluation of older individuals with possible idiopathic pulmonary fibrosis should attempt to obtain a definitive diagnosis while minimizing the risk of injury to the patient. Subsequent treatment of older patients with idiopathic pulmonary fibrosis should include individualized, purposeful therapy that optimizes the patient’s quality of life and survival while reducing the serious adverse effects associated with the recommended therapy. This article outlines and examines the key issues clinicians face when evaluating and treating idiopathic pulmonary fibrosis in older adults. How is the diagnosis confirmed in older patients? Idiopathic pulmonary fibrosis is one of the many potential diagnoses for patients with recently recognized interstitial lung disease. Therefore, the most basic and important step in providing the best care for older adults with interstitial lung disease is the diagnosis of idiopathic pulmonary fibrosis. The American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Society have issued a unanimous statement on the diagnosis and treatment of idiopathic pulmonary fibrosis: to provide a valid diagnostic method to evaluate patients for potential IPF. Clinical symptoms in most elderly patients with new-onset interstitial lung disease include dyspnea, cough, or fatigue. In a small number of cases, the diagnosis is confirmed by incidental detection of interstitial abnormalities while taking radiographs for other purposes. As screening CT scans of the chest become more widely accepted, the number of elderly patients with interstitial lung disease is likely to increase. The initial evaluation of a patient with suspected interstitial lung disease should include a detailed physical examination, which may differ in the presence of wet rales at the base of the lungs on auscultation as well as pestle and mortar fingers. Pulmonary function tests usually demonstrate a reduction in exertional lung volume and total lung volume as well as a reduction in the diffusing capacity of the lungs for carbon monoxide in one breath. If clinical signs, symptoms, and physiology are consistent with restrictive lung disease, then idiopathic pulmonary fibrosis is diagnosed. The best test for diagnostic imaging evaluation is a non-contrast, high-resolution CT (HRCT) scan (1-2 mm layer thickness), which is a full range of exhalation and inhalation imaging performed while the patient is in the supine and prone positions, respectively. The results are consistent with the diagnosis of common interstitial pneumonia confirmed in HRCT scan mode, which allows clinicians to confirm the diagnosis of idiopathic pulmonary fibrosis based on HRCT. HRCT scan features include subpleural changes, significant effects of the pulmonary stroma, lattice-like changes, foveal changes with or without distended bronchial dilatation, and a lack of features inconsistent with the common type of interstitial pneumonia. The diagnostic predictive accuracy of idiopathic pulmonary fibrosis is high in older adults who demonstrate extensive interstitial fibrosis on HRCT scans. The next (and crucial) step is to rule out other factors, including pulmonary toxic drug reactions from some commonly used drugs (e.g., amiodarone, methotrexate, furantoin), interstitial lung disease associated with tuberous histopathy, and interstitial lung disease caused by occupational and environmental exposures. There are other diseases that are highly similar to idiopathic pulmonary fibrosis, such as nonspecific fibrosing interstitial pneumonia and chronic allergic pneumonia. Clinical evaluation of patients with suspected idiopathic pulmonary fibrosis should include serologic testing to rule out common autoimmune processes that may be interstitial lung disease, as subsequent therapeutic measures are strongly influenced by this. However, we should be aware that autoantibody positivity grows with age. Therefore, neither positive rheumatoid serology nor low-level expression of antinuclear antibodies are specific to tuberous histopathy and cannot be used alone for diagnosis, but idiopathic pulmonary fibrosis is only taken into consideration if other tuberous histopathies are excluded. Surgical lung biopsy is considered in elderly patients who cannot be diagnosed with common interstitial pneumonia on HRCT scan. There are recognized potential complications associated with performing a biopsy and this decision should be taken seriously, especially in frail older adults. The potential risks and benefits should be discussed in depth with the patient, especially emphasizing that the results of the surgical lung biopsy will influence the subsequent treatment plan. In addition, the patient’s age is a predictor of the presence of idiopathic pulmonary fibrosis; therefore, the need for biopsy decreases with age in any clinical situation. If a biopsy is performed, the histopathologic presentation of common interstitial pneumonia provides the diagnosis of idiopathic pulmonary fibrosis after other diseases have been excluded.